% | $
Quotes you view appear here for quick access.

Osiris Therapeutics, Inc. Message Board

  • hwmccusker hwmccusker Mar 7, 2013 1:20 PM Flag


    The Bottom Line: Osiris leaped to $9.61 from $6.91 on Wednesday after had managed to keep its Q4 loss in better check than what analysts had forecast. For Osiris, it was also a year of commercial transformation, having 4 products on the market and expanding capabilities in development, manufacturing, sales and marketing. OSIR’s Q4/12, was narrower than one consensus estimate of a loss of $0.15 cents. However, FY11 earnings were -$0.15 per share. Revenues were slightly below Estimate of $3.1 M but well above the year-ago revenues of $0.8 M.OSIR is still working with regulatory agencies across the world to provide them with the information needed to approve Prochymal. Osiris is studying Prochymal for several indications including Crohn’s disease and acute myocardial infarction, which are blockbuster indications. As far as the Crohn’s disease indication is concerned, OSIR said that enrollment for a P3 study continues. OSIR is actively looking for a partner for Prochymal. Last year, Osiris had regained commercial rights for Prochymal and Chrondogen from Sanofi (SNY). OSIR is trading well above their 50 moving averages. Sell – OSIR was UP in the pre-market … but, has been trading DOWN -$0.23 or -2.46% to $9.07 – a SELL on strength – let is settle down and come back.

    Sentiment: Sell

10.52+0.26(+2.53%)Dec 1 4:00 PMEST